<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Clin Exp Immunol 2000; 119:299&#194;&#177;304 <br />  <br />  <br />  <br />  <br />    Virulent avirulent (dhfr-ts ) Leishmania major elicit predominantly type-1 <br />                       cytokine response human cells vitro <br />  <br />    C. BRODSKYN*&#194;&#178;, S. M. BEVERLEY&#194;&#179; <span id='am-1' about='obo:IMR_0200083' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-2' property="rdfs:label" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-3' property="oboInOwl:hasExactSynonym" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-4' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-5' property="oboInOwl:id" content="IMR:0200083" datatype="xsd:string"></span><span id='am-6' property="oboInOwl:hasDbXref" content="KEGG:C00020" datatype="xsd:string"></span><span id='am-7' property="rdfs:label" content="AMP" datatype="xsd:string"></span>amp</span>; R. G. TITUS&#194;&#178; *Laborato&#195;&#8218;rio Imunologia, Departamento Biointerac&#195;&#8249;a&#195;&#8218;o, <br />           Instituto Cie&#195;&#402;ncias da Sau&#195;&#8218;de, Universidade Federal da Bahia, Bahia, Brazil, &#194;&#178;Department Pathology, <br />           College Veterinary Medicine Biomedical Sciences, Colorado State University, Fort Collins,                      &#194;&#179;Department Molecular Microbiology, Washington University, St Louis, MO, USA <br />  <br />  <br />                                                  (Accepted publication 15 October 1999) <br />  <br />  <br />  <br />                                                                  SUMMARY <br />                  study compared immune response normal human cells cultured vitro                  virulent strains Leishmania major (CC1 LV39), avirulent vaccine strain (dhfr-ts )                  targeted deletion essential gene DHFR-TS. utilized vitro naive T <br />                  cells normal human donors primed autologous Leishmania-infected macrophages.                  parasites infected macrophages transformed amastigotes cells.  <br />                  LV39 CC1 replicated macrophages, dhfr-ts did  peripheral blood <br />                  lymphocytes (PBL) stimulated autologous macrophages infected                  parasites, lymphocytes produced type-1-biased cytokine response. Finally, addition 12 <br />                  &#194;&#174;rst stimulation period increased production interferon-gamma decreased 5 <br />                  secretion. hand, anti 12 resulted opposite effect. <br />  <br />                  Keywords      Leishmania major macrophages          Th1    Th2 12 <br />  <br />  <br />  <br />  <br />                        INTRODUCTION                                        interactions occur parasite host.                                                                            alternative method studying interactions use Protozoan parasites genus Leishmania reside macro- <br />                                                                            vitro mimics vivo infection. Shankar &amp; Titus [3] <br /> phages, causing spectrum diseases humans ranging                                                                            developed vitro using cells lymphoid tissues mild cutaneous lethal visceral leishmaniasis. Cell-mediated <br />                                                                            naive mice L. major promastigotes showed immune responses critical resistance recovery                                                                            mimicked vivo responses murine leishmaniasis.  leishmaniasis [1]. <br />                                                                            report developed vitro cell priming (IV) <br />     Cytokines central elements development                                                                            using peripheral blood mononuclear cells (PBMC) normal <br /> immune response, human experimental leish- <br />                                                                            donors assay naive peripheral blood lymphocytes <br /> maniasis received great deal attention. Cure                                                                            (PBL) sensitized autologous Leishmania-infected <br /> related predominance Th1 response, leads                                                                            macrophages. production interferon-gamma (IFN-g) activation                                                                                Recently, Titus et al. [4] tested safety vaccination <br /> parasite-infected macrophages [2]. contrast, Th2 response <br />                                                                            potential conditional auxotroph L. major (dhfr-ts ) production 4 10 results disease <br />                                                                            produced targeted deletion essential metabolic gene, <br /> progression [2]. Efforts focused understanding early <br />                                                                            DHFR-TS (dihydrofolate reductase-thymidylate synthase). events uence development Th1 Th2 cells                                                                            shown dhfr-ts engulfed murine macrophages, trans- <br /> interplay cytokines phenomenon order                                                                            formed amastigotes macrophages, survived mice determine role Th development. <br />                                                                            2 months elicited substantial protective immune response     patients infected Leishmania, dif&#194;&#174;cult estimate <br />                                                                            susceptible BALB/c mice, indicated resistance subse- time initial infection. result study early <br />                                                                            quent challenge virulent parasites [4]. addition, Veras et al. <br />     Correspondence: Dr Richard Titus, Department Pathology, College     (5) observed mice vaccinated dhfr-ts partially Veterinary Medicine Biomedical Sciences, Colorado State Univer-     protected subsequent challenge L. amazonensis. <br /> sity, Fort Collins, 80523, USA.                                          studied capacity dhfr-ts sensitize PBL <br />     E-mail: rtitus@cvmbs.colostate.edu                                     IV  <br /> q 2000 Blackwell Science                                                                                                                    299 <br />  300                                           C. Brodskyn, S. M. Beverley &amp; R. G. Titus <br />               MATERIALS METHODS                                            IV                                                                                step IV assay used study depicted Fig. 1. Parasites <br />                                                                                blood collection 1 obtained macrophages served different types Leishmania used study: <br />                                                                                antigen-presenting cells (APC). Human blood obtained dhfr-ts (line E-10), avirulent form L. major, produced                                                                                healthy individuals Student Health Center Colorado State <br /> targeted deletion essential metabolic gene DHFR-TS <br />                                                                                University. PBMC obtained heparinized venous blood <br /> (dihydrofolate reductase-thymidylate synthase [3]); CC1,                                                                                passage Ficoll&#194;&#177;Hypaque gradient [7]. cells attenuated clone L. major dhfr-ts derived; <br />                                                                                washed resuspended RPMI 1640 medium, supplemented clone 5 LV 39 line Rho/SV/59/P, virulent clone L. <br />                                                                                2 mM <span id='am-13' about='obo:IMR_0200448' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0001695 obo:IMR_0000001'><span id='am-14' property="oboInOwl:hasDbXref" content="KEGG:C00064" datatype="xsd:string"></span><span id='am-15' property="rdfs:label" content="L-Glutamine" datatype="xsd:string"></span><span id='am-16' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-17' property="oboInOwl:id" content="IMR:0200448" datatype="xsd:string"></span>L-glutamine</span>, 100 U/ml penicillin, 100 mg/ml strepto- <br /> major passed mice 2 weeks maintain <br />                                                                                mycin, 10 mg/ml gentamycin 10% heat-inactivated AB human <br /> virulence. used vitro experiments, Leishmania                                                                                serum (Pel-Freez; Clynical  Brown Deer, WI), termed <br /> grown biphasic NNN medium [6] promastigotes                                                                                complete medium, concentration 4 &#194;&#180; 106 cells/ml. harvested stationary phase growth. dhfrt-ts lack <br />                                                                                cells plated 24 plates (Costar, Corning , Corning, DFHR-TS gene, conditional auxotroph                                                                                NY) incubated 2 h 378C, 5% <span id='am-8' about='obo:IMR_0200324' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-9' property="oboInOwl:id" content="IMR:0200324" datatype="xsd:string"></span><span id='am-10' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-11' property="oboInOwl:hasDbXref" content="KEGG:C00011" datatype="xsd:string"></span><span id='am-12' property="rdfs:label" content="CO2" datatype="xsd:string"></span>CO2</span>. Non-adherent cells <br /> cultured presence 10 mg/ml <span id='am-18' about='obo:IMR_0200384' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-19' property="oboInOwl:hasDbXref" content="KEGG:C00214" datatype="xsd:string"></span><span id='am-20' property="rdfs:label" content="Thymidine" datatype="xsd:string"></span><span id='am-21' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-22' property="oboInOwl:id" content="IMR:0200384" datatype="xsd:string"></span>thymidine</span>. <br />                                                                                removed plates adherent cells (APC-1, Fig. 1) <br />                                                                                cultured (378C, 5% CO2) complete medium 7 days. <br /> Survival Leishmania macrophages vitro                                 24 h culture, APC-1 infected dhfr-ts , order test ability dhfr-ts survive human                    CC1 LV39 parasite:cell ratio 5:1 (348C, 5% CO2). <br /> macrophages vitro, cells adhered glass coverslips               Cultures washed order remove free parasites. culture 7 days infected dhfr-ts , CC1                     blood collected volunteer (day 7, <br /> LV39 ratio &#194;&#174;ve parasites macrophage.                        Fig. 1) PBMC plated 4 &#194;&#180; 106 cells/ml 24 plates <br /> coverslips removed intervals (24, 48                    order obtain autologous lymphocytes (non-adherent PBMC) <br /> 72 h), stained Diff-Quick (Scienti&#194;&#174;c Products, McGaw,                  APC restimulation (adherent cells, APC-2, Fig. 1). examined light microscopy presence intracellular             2 h incubation (378C, 5% CO2), non-adherent PBMC parasites.                                                                     harvested resuspended complete medium concentration <br />                                                                                4 &#194;&#180; 106 cells/ml. cells added Leishmania-infected <br /> Cytokines monoclonal antibodies                                            APC-1 7 days 378C, 5% CO2. incubation, Recombinant human 12 (supplied Bioanalytical                         blast cells 85% CD4&#194;&#8225; T cells harvested Sciences Department Genetics Institute, , Cambridge,                    restimulated using autologous Leishmania-infected macrophages <br /> MA) used concentration 2&#194;&#180;5 mg/ml. Anti-human                       (infected APC-2, Fig. 1) 48 h 378C, 5% CO2. super- 12 (clone 8.6; PharMingen, San Diego, CA) used                     natants collected kept 208C tested cytokine <br /> concentration 10 mg/ml.                                                     content ELISA. <br />  <br />  <br />  <br />                     Day 0                                     Blood collection 1 <br />  <br />  <br />  <br />                                                                                                 PBMC APC <br />                                                                                                 APC-1 <br />  <br />  <br />  <br />                                                                                                  Infection APC-1 <br />                                                           Day 6 <br />  <br />                                                               Blood collection 2 <br />                    Day 7 <br />                                                                                                Non-adherent PBMC <br />                         PBMC APC-2 <br />  <br />                                                                                               Non-adherent PBMC + <br />                    Day 13                                                                     infected APC-1 <br />  <br />                         Infection APC-2                 Day 14                                                            Day 16 <br />  <br />                                                              Stimulated non-adherent                            Supernatants <br />                                                              PBMC + infected APC-2                              ELISA <br />  <br />  <br />       Fig. 1. Experimental approach used vitro cell priming (IV) assays. blood collection 1 APC-1 obtained,       infected 6 days different types Leishmania used study. blood collection 2 autologous non-adherent peripheral <br />       blood mononuclear cells (PBMC) obtained incubated infected APC-1 7 days generate T cell blasts APC-2 <br />       used restimulation. hours harvesting blast cells  e. day 13), APC-2 infected different <br />       types Leishmania. day 14 experiment, blast cells collected incubated infected APC-2 48 h. supernatants <br />       obtained cultures analysed levels IFN-g 5. <br />                                                                   q 2000 Blackwell Science  Clinical Experimental Immunology, 119:299&#194;&#177;304 <br />                                                     Studies leishmaniasis using human vitro                                             301 <br /> Cytokine assays                                                                 replicate human macrophages vitro. infected <br /> Levels IFN-g 5 present supernatants harvested 48 h                 human macrophages, obtained normal human donors, restimulation determined using commercial ELISA                  dhfr-ts , CC1 LV39 ratio &#194;&#174;ve parasites kits (R&amp;D Systems, Minneapolis, MN).                                            macrophage. types parasites phagocytized macro- <br />     12 levels quanti&#194;&#174;ed 24, 48 96 h supernatants             phages &#194;&#174;rst 24 h (Fig. 2). 24 h, virulent Leishmania <br /> harvested infected uninfected macrophage cultures using                replicated amastigotes macrophages (Fig. 2). contrast, <br /> immunoassay kits (R&amp;D Systems) speci&#194;&#174;c 12 p40 p70                    dhfr-ts did replicate. rm inability dhfr-ts <br /> subunits. experiments supernatants obtained               survive macrophage lack DHFR-TS, &#194;&#174;rst period stimulation (7 days culture presence                added thymidine (10 mg/ml) medium; restored infected macrophages PBL) harvested                     survival replication (Fig. 2). IFN-g, 5 12 present supernatants determined ELISA.                                                            Cytokine production <br />                                                                                 Using IV assay depicted Fig. 1, production IFN-g <br /> Statistical analysis                                                            5 quanti&#194;&#174;ed, cytokines considered <br /> Comparisons production cytokines, using different types               representative Th1 Th2 responses, respectively [1]. initial Leishmania, determined using ANOVA test. Comparisons group  test effect cytokine anti-cytokine <br /> treatment) use Student&apos;s t-test. tests performed <br /> using Sigma-Stat software (Microsoft . Differences considered signi P # 0&#194;&#180;05. <br />  <br />                                              RESULTS <br /> Inability dhfr-ts replicate macrophages vitro shown dhfr-ts able replicate murine <br /> macrophages [3].  tested parasites <br />  <br />                                       dhfr-ts&#226;&#8364;&#8220; <br />                                       dhfr-ts&#226;&#8364;&#8220; + Thymidine (10 &#194;&#181;g/ml) <br />                                       CC1 <br />                                       LV39 <br />  <br />                                1600 <br />  <br />  <br />                                1400 <br />  Amastigotes/100 macrophages <br />  <br />  <br />  <br />  <br />                                1200 <br />  <br />  <br />                                1000 <br />  <br />  <br />                                800 <br />  <br />  <br />                                600 <br />  <br />  <br />                                400 <br />  <br />  <br />                                200                                              Fig. 3. Levels IFN-g 5 present supernatants collected                                                                                 vitro cell priming (IV) assays. Non-adherent peripheral blood <br />                                                                                 mononuclear cells (PBMC) normal donors cultured                                  0 <br />                                        24            48             72          autologous infected uninfected macrophages 7 days,                                                                                 period restimulated 48 h, employing autologous <br />                                                                                 infected macrophages. Supernatants collected cytokine levels <br /> Fig. 2. Inability dhfr-ts replicate human macrophages vitro.        determined ELISAs.   Production IFN-g (pg/ml). (b) Production Human macrophages obtained peripheral blood mononuclear cells              5 (pg/ml). triangle represents individual donor. Concentrations <br /> (PBMC) infected stationary phase Leishmania 5:1 ratio            IFN-g 5 cultures uninfected macrophages (Leishmania:macrophage). indicated times, cells &#194;&#174;xed, stained       subtracted. levels IFN-g obtained cultures uninfected Diff-Quick examined light microscopy number              macrophages ranged 0&#194;&#180;0 270&#194;&#180;0 pg/ml levels 5 <br /> intracellular parasites. macrophages/donor counted        cultures 0&#194;&#180;0 5&#194;&#180;5 pg/ml. time number intracellular amastigotes. Results shown      signi differences (P &gt; 0&#194;&#180;05) different groups infected mean 6 s.e.m. samples group.                                  dhfr-ts , CC1 LV39 concerning production IFN-g 5. <br />  <br /> q 2000 Blackwell Science  Clinical Experimental Immunology, 119:299&#194;&#177;304 <br />  302                                           C. Brodskyn, S. M. Beverley &amp; R. G. Titus <br /> experiments attempted measure 4 production cultures, 4 consistently detected, presumably consumption cytokine proliferating cells. <br /> Figure 3 shows concentration IFN-g 5 obtained using <br /> Leishmania-infected adherent cells (APC) autologous non- <br /> adherent cells. types parasites able induce production IFN-g signi differences observed responses generated using dhfr-ts , CC1 L. major <br /> (P &gt; 0&#194;&#180;05). signi differences observed  <br /> cerning production 5, PBMC donors                Fig. 5. Effect 12 IFN-g   5 (b) production obtained did produce cytokine IV assay. Based            stimulation non-adherent peripheral blood mononuclear cells (PBMC) <br /> results conclude donors (6/10) used              autologous Leishmania-infected macrophages normal human <br /> study secreted high amounts IFN-g, 5 production                donors. Non-adherent PBMC different donors exposed practically non-detectable (&lt; 10 pg/ml).  cells              autologous dhfr-ts -infected macrophages 7 days presence donors produced predominantly type-1 cytokines.                      absence 12, period blast cells restimulated                                                                              autologous dhfr-ts -infected macrophages 48 h. supernatants donors produced 5 signi amounts addition                                                                              collected IFN-g 5 levels determined ELISA. IFN-g, characteristic Th0 response. donors          differences groups treatment (absence presence considered non-secretor, IFN-g               12) statistically signi (P &lt; 0&#194;&#180;05) concerning secretion 5 produced low. noted pro&#194;&#174;le            IFN-g 5. <br /> cytokines observed altered supernatants harvested 7 days culture using Leishmania-infected APC-1 48 h second stimulation using infected APC-2 (data          collected supernatants cultures 24, 48 96 h later. shown).                                                                      detect 12 cultures (data shown). <br />                                                                               autologous PBL cultured Leishmania- <br /> Importance 12 generation Th1 responses                       infected macrophages 7 days, 12 produced (Fig. 4). 12 received great deal attention leishmaniasis,         signi differences 12 secretion observed responsible development Th1 response.              different groups infected dhfr-ts , CC1 LV39 (P &gt; 0&#194;&#180;05). <br /> determined 12 produced IV                        order determine importance 12 develop- <br /> infected macrophages dhfr-ts , CC1 LV 39                  ment Th1 response IV  cultures initiated                                                                              presence absence recombinant human 12 anti- <br />                                                                              human 12. cytokine antibody added cultures <br />       250                                                                    &#194;&#174;rst stimulation PBL, using infected macrophages                                                                              APC. primary stimulation, blasts harvested                                                                              restimulated autologous infected macrophages APC       200                                                                    absence 12 anti 12. shown Fig. 5, 12 <br />                                                                              signi&#194;&#174;cantly increased production IFN-g (P &lt; 0&#194;&#180;05)                                                                              cells donors tested (Fig. 5a). hand, cytokine <br />       150 <br />                                                                              led signi decrease (P &lt; 0&#194;&#180;05) secretion 5                                                                              levels non-detectable (Fig. 5b). <br />       100 <br />  <br />  <br />        50 <br />  <br />  <br />         0 <br />  <br />  <br />  <br />                     dhfr-ts&#226;&#8364;&#8220;        CC1           LV39 <br />  <br />                                  Treatment <br /> Fig. 4. 12 cultures Leishmania-infected macrophages non- <br /> adherent peripheral blood mononuclear cells (PBMC). Macrophages         Fig. 6. Effect anti 12 IFN-g   5 (b) production obtained <br /> 10 different donors infected dhfr-ts , CC1 LV39     stimulation non-adherent peripheral blood mononuclear cells <br /> ratio &#194;&#174;ve parasites macrophage. washing remove free       (PBMC) autologous Leishmania-infected macrophages normal <br /> parasites, autologous non-adherent PBMC added cultures       human donors. Non-adherent PBMC &#194;&#174;ve different donors incubated 7 days 378C, 5% CO2. point supernatants    exposed autologous dhfr-ts -infected macrophages 7 days harvested 12 levels determined ELISA speci&#194;&#174;c       presence absence anti 12,  period blast cells p40 p70 subunits 12. Concentrations 12 produced           restimulated autologous dhfr-ts -infected macrophages 48 h. cultures uninfected macrophages subtracted. levels     supernatants collected IFN-g 5 levels deter- 12 obtained cultures uninfected macrophages        mined ELISA. signi differences (P &lt; 0&#194;&#180;05) 9&#194;&#180;0 70&#194;&#180;0 pg/ml. signi differences (P &gt; 0&#194;&#180;05)          groups treatment (absence presence anti 12) concerning different groups infected dhfr-ts , CC1or LV39.             production IFN-g 5. <br />                                                                   q 2000 Blackwell Science  Clinical Experimental Immunology, 119:299&#194;&#177;304 <br />                                       Studies leishmaniasis using human vitro                                                  303 <br />     role endogenous 12 examined using anti-            Leishmania induce contrasting signals leading production 12 &#194;&#174;rst stimulation PBL. shown Fig. 6,         tumour necrosis factor-alpha (TNF , leads macro- <br /> presence anti 12 primary stimulation led            phage activation, production transforming growth <br /> signi decrease production IFN-g (Fig. 6a) cells       factor-beta (TGF-b) 10, linked macrophage &#194;&#174;ve donors tested (P &lt; 0&#194;&#180;05). addition, anti 12              deactivation inhibition IFN-g [13,14]. uence enhanced production 5 (Fig. 6b) cells              IFN-g produced natural killer (NK) cells, depend <br /> donors (P &lt; 0&#194;&#180;05). interesting presence antibody   12, involved initial Th1 development [15]. Initial primary stimulation PBL donors, normally           survival Leishmania inside macrophage probably depends <br /> did produce 5, induced secretion cytokine,             similar cytokines predominate micro- <br /> showing importance 12 generation different            environment infection. IV model allows study early <br /> Th responses.                                                             events phagocytosis Leishmania macrophages                                                                           modulation immune responses addition cytokines <br />                                                                           anti-cytokines. <br />                           DISCUSSION <br />                                                                               12 received great deal attention leishmaniasis. results vitro priming shown              cytokine produced following infection mice L. major <br /> correlate vivo responses murine leishmaniasis [3].        [16,17] important control Th2 expansion promote succeeded generating autologous              predominance Th1-type response [18&#194;&#177;20]. addition, <br /> infected macrophages serve APC priming PBL normal             treatment susceptible mice 12 renders resistant <br /> human donors. IV approach allowed examine inter-               [19,21,22].  12 used effective adjuvant <br /> actions occur infected APC PBL. inter-              killed vaccine L. major [23]. contrast vivo <br /> actions uence overall response infection               results, L. major inhibits 12 production infected murine <br /> Leishmania outcome disease. studies            macrophages vitro [17,24]. Similar studies mice, possible using cells patients leishmaniasis       detect secretion 12 L. major-infected macro- impossible determine patient infected       phages, suggesting parasites induce production parasite.                                                             cytokine human macrophages. Interestingly,  <br />      analysed ability different Leishmania parasites      addition autologous PBL infected macrophage cultures prime T cells IV  dhfr-ts , CC1 L. major             resulted detectable production 12 (Fig. 4). suggests <br /> (strain LV39). dhfr-ts engulfed macrophages,           signals delivered PBL, CD40&#194;&#177;CD40L [25], <br /> did replicate inside cells (Fig. 2). Interestingly, despite   important regulation 12 production fact dhfr-ts did replicate macrophages, elicited       human macrophages infected L. major. men- <br /> type immune response (potentially protective IFN-g little         tioned contrast results study L. major, 5) did CC1 LV39 (Fig. 3).  dhfr-ts                Russo et al. [8] observed 12 secretion L. amazonensis- <br /> avirulent induces protective immune response,          infected macrophages 96 h infection. apparent acceptable vaccine candidate human use.                            difference explained use different strains      Evaluating cytokine production (IFN-g 5) response          Leishmania; progression infection L. amazonensis stimulation parasite-infected macrophages, observed            mice shown distinct L. major [26]. donors elicited Th1 Th0 phenotype. 10 donors                Studies human leishmaniasis rm relevant roles tested, showed Th1 pro&#194;&#174;le, Th0 considered         IFN-g 12 major cytokines involved host protection non-secretor. Similar results obtained Russo et al. [8],        [1].  studying effects 12 anti 12 developed vitro study early responses            IV important understand development unexposed individuals L. amazonensis infection. authors            Leishmania-speci&#194;&#174;c Th1 responses. depicted Fig. 5, 12 <br /> obtained different cell lines different donors veri&#194;&#174;ed      completely abrogated Th2 responses, increasing signi&#194;&#174;cantly classi&#194;&#174;ed Th1 Th0 responders.                 secretion IFN-g abolishing production 5 cells  independent Leishmania used, human cells                donors stimulated Leishmania-infected macro- <br /> produce similar cytokine pro&#194;&#174;le.                                        phages. hand, presence anti 12      Subauste et al. [9], studying responses unexposed           IV promoted Th2 response, signi decrease IFN-g <br /> individuals Toxoplasma gondii infection vitro model,          production increase 5 (Fig. 6), showing important <br /> observed intense proliferation CD4&#194;&#8225; ab T cells,           role 12 differentiation human Th1 Th2 <br /> cells secreted signi IFN-g.          responses.  vaccine potential dhfr-ts leish- <br /> rapid T cell response play important role early             maniasis enhanced transfecting parasite response intracellular parasites.  recent work Launois       cytokine genes (e.g. 12) favour development Th1 <br /> et al. [10] showed large amounts cytokines  4          responses. work) secreted mouse ab T cells &#194;&#174;rst 16 h infection L. major. Finally, results obtained                          ACKNOWLEDGMENTS <br /> experiments concerning production IFN-g 5                                                                           thank Genetic Institute providing human recombinant 12, <br /> similar observed leishmaniasis patients;                                                                           Monica Estay technical assistance Dr Greg DeKrey Dr <br /> patients self-healing cutaneous leishmaniasis strong            Lamine Mbow critical review manuscript. study received <br /> Th1 responses [2,11]  early infection, Th0 pattern [12].      &#194;&#174;nancial support NIH AI-29955 (R.G.T.), NIH AI 29646      Th1&#194;&#177;Th2 dichotomy probably uenced cyto-             Special Programme Tropical Disease Research (S.M.B.). C.B. received kines produced early stages Leishmania survival            fellowship CAPES/Fulbright 1997 CAPES-Brasilia/ <br /> inside macrophage. entry human macrophages,                 Brazil 1998. <br /> q 2000 Blackwell Science  Clinical Experimental Immunology, 119:299&#194;&#177;304 <br />  304                                           C. Brodskyn, S. M. Beverley &amp; R. G. Titus <br />                                                                              14 Barral-Netto M, Badaro R, Barral et al. Tumor necrosis factor <br />                           REFERENCES <br />                                                                                 (cachectin) human visceral leishmaniasis. J Infec Dis 1991; <br />  1 Barral-Netto M, Machado P, Bittencourt AL, Barral  Recent                  163:853&#194;&#177;7. <br />    advances pathophysiology treatment human cutaneous              15 Scharston-Kersten T, Scott P. role innate immune response    leishmaniasis. Curr Opin Dermatol 1997; 4:51&#194;&#177;8.                              Th1 cell development following Leishmania major infection. J Leuk <br />  2 Carvalho EM, Correia Filho D, Bacellar O, Almeida RP, Rocha E.               Biol 1995; 57:515&#194;&#177;22. <br />    Characterization immune response subjects self-healing     16 Sypek JP, Chung CL, Mayor SE et al. Resolution cutaneous <br />    cutaneous leishmaniasis. J Trop Med Hyg 1995; 53:273&#194;&#177;7.                   leishmaniasis: interleukin 12 initiates protective T helper type 1 <br />  3 Titus RG, Gueiros-Filho FJ, Freitas LA, Beverley SM. Development          immune response. J Exp Med 1993; 177:1797&#194;&#177;802. <br />    safe live Leishmania vaccine line gene replacement. Proc Natl        17 Reiner SL, Zheng S, Wang ZE, Stowring L, Locksley RM. Leishmania <br />    Acad Sci USA 92 1995; 92:10267&#194;&#177;71.                                           promastigotes evade interleukin 12  12) stimulate broad range <br />  4 Shankar AH, Titus RG. Leishmania-major-speci&#194;&#174;c, CD4&#194;&#8225;, major                  cytokines CD4&#194;&#8225; T cells initiation infection. J Exp <br />    histocompatibility complex class II-restricted T cells derived          Med 1994; 179:447&#194;&#177;56. <br />    lymphoid tissues naive mice. J Exp Med 1993; 78:101&#194;&#177;11.                18 Scharston-Kersten T, Afonso LC, Wysocka M, Trinchieri G, Scott P. <br />  5 Veras P, Brodskyn CI, Balestieri FM, Freitas LAR, Ramos APS,                 12 required natural killer activation subsequent <br />    Queiroz ARP, Beverly SM, Barral-Netto MA. dhfr-ts Leishmania                 development experimental leishmaniasis. J Immunol 1995; <br />    major knockout mutant cross protects Leishmania amazonensis.         154:5320&#194;&#177;30. <br />    Memorias Instituto Osvaldo Cruz 1999; 94:491&#194;&#177;6.                        19 Murray HW, Hariprashad J, Coffman RL. Behavior visceral <br />  6 Titus RG, Muller  Kimsey P, Cerny  Behin R, Zinkernagel RM,              Leishmania donovani experimentally induced T helper 2 (Th2)- <br />    Louis JA. Exacerbation experimental murine cutaneous leish-               associated response model. J Exp Med 1997; 185:867&#194;&#177;74. <br />    maniasis CD4&#194;&#8225; Leishmania major-speci&#194;&#174;c <br /> </body></html>